Barclays PLC Axsome Therapeutics, Inc. Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 220,098 shares of AXSM stock, worth $16.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

220,098

Previous 191,862 14.72%

Holding current value

$16.2 Million

Previous $15.3 Million 15.02%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$69.39 - $97.64 $1.96 Million - $2.76 Million	28,236 Added 14.72%	220,098 $17.6 Million
Q4 2023 Feb 15, 2024	BUY	$57.42 - $83.61 $10.1 Million - $14.6 Million	175,052 Added 1041.36%	191,862 $15.3 Million
Q3 2023 Nov 07, 2023	BUY	$69.25 - $82.21 $1.16 Million - $1.38 Million	16,737 Added 22927.4%	16,810 $1.18 Million
Q2 2023 Aug 03, 2023	BUY	$58.41 - $90.35 $4,263 - $6,595	73 New	73 $5,000
Q3 2022 Nov 03, 2022	BUY	$36.06 - $69.85 $958,186 - $1.86 Million	26,572 New	26,572 $1.19 Million

Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $48,229 - $68,118	-1,571 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$19.91 - $68.26 $1.04 Million - $3.56 Million	-52,146 Reduced 97.08%	1,571 $52,000
Q2 2021 Aug 13, 2021	BUY	$50.63 - $73.5 $945,819 - $1.37 Million	18,681 Added 53.32%	53,717 $3.62 Million
Q1 2021 May 13, 2021	BUY	$55.91 - $81.44 $1.32 Million - $1.92 Million	23,604 Added 206.47%	35,036 $1.98 Million
Q3 2020 Nov 12, 2020	SELL	$68.34 - $85.84 $434,710 - $546,028	-6,361 Reduced 35.75%	11,432 $815,000
Q2 2020 Aug 12, 2020	SELL	$49.87 - $98.69 $831,731 - $1.65 Million	-16,678 Reduced 48.38%	17,793 $1.46 Million
Q1 2020 May 13, 2020	SELL	$41.2 - $101.31 $1.28 Million - $3.14 Million	-30,967 Reduced 47.32%	34,471 $2.03 Million
Q4 2019 Feb 10, 2020	BUY	$16.71 - $106.24 $926,368 - $5.89 Million	55,438 Added 554.38%	65,438 $6.76 Million
Q3 2019 Nov 14, 2019	SELL	$20.24 - $29.16 $721,758 - $1.04 Million	-35,660 Reduced 78.1%	10,000 $202,000
Q2 2019 Aug 14, 2019	BUY	$13.46 - $25.75 $612,228 - $1.17 Million	45,485 Added 25991.43%	45,660 $1.18 Million
Q1 2019 May 15, 2019	SELL	$2.63 - $16.34 $27,154 - $168,710	-10,325 Reduced 98.33%	175 $2,000
Q4 2018 Feb 14, 2019	BUY	$2.0 - $4.15 $21,000 - $43,575	10,500 New	10,500 $30,000
Q3 2018 Nov 14, 2018	SELL	$2.3 - $3.55 $83,950 - $129,575	-36,500 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.15 - $3.6 $1,935 - $3,240	900 Added 2.53%	36,500 $117,000
Q1 2018 May 15, 2018	BUY	$2.35 - $5.6 $83,660 - $199,360	35,600 New	35,600 $87,000
Q4 2017 Feb 14, 2018	SELL	$4.45 - $6.2 $77,875 - $108,500	-17,500 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$4.65 - $6.1 $81,375 - $106,750	17,500	17,500 $97,000

Others Institutions Holding AXSM

# of Institutions

290

Shares Held

37.1M

Call Options Held

401K

Put Options Held

464K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.15B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account